LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.18 USD | -1.52% |
|
+2.34% | 0.00% |
| 04-15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| 04-15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.18
USD
Average target price
36.75
USD
Spread / Average Target
+127.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 420M | |
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target
